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Abstract  
Ovarian cancer is not a single disease and can be subdivided into at least five different 
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histological subtypes that have different identifiable risk factors, cells of origin, molecular 
compositions, clinical features and treatments. Ovarian cancer is a global problem, is typically 
diagnosed at late stage, and has no effective screening strategy.  Standard treatments for newly 
diagnosed cancer consist of cytoreductive surgery and platinum-based chemotherapy. In recurrent 
cancer, chemotherapy, anti-angiogenic agents, and poly (ADP ribose) polymerase (PARP) 
inhibitors are used and immunological therapies are currently being tested. High-grade serous 
carcinoma (HGSC) is the most commonly diagnosed form of ovarian cancer and is typically very 
responsive to platinum-based chemotherapy at diagnosis. However, in addition to the other 
histologies, HGSCs frequently relapse and become increasingly resistant to chemotherapy. 
Consequently, understanding the mechanisms underlying platinum resistance and finding ways to 
overcome them are active areas of study in ovarian cancer. Significant progress has been made in 
identifying genes associated with high risk of ovarian cancer (such as BRCA1 and BRCA2) as 
well as a precursor lesion of HGSC called a serous tubal intraepithelial carcinoma, which hold 
promise for identifying individuals at high risk of developing the disease and for developing 
prevention strategies.  
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[H1] Introduction  
Although once considered a single entity, ovarian cancer can be subdivided into different 
histological subtypes that have different identifiable risk factors, cells of origin, molecular 
compositions, clinical features and treatments. These histological subtypes include epithelial 
cancers which account for ~90% of ovarian cancers and include serous, endometrioid, clear cell 
and mucinous carcinomas (Figure 1, Table 1). Of these types, high grade serous carcinoma 
(HGSC) is the most commonly diagnosed. Histologically and clinically, low-grade endometrioid 
and low serous carcinomas are different compared to their high-grade counterparts; HGSC is 
similar to high-grade endometrioid carcinomas (98, 100, 101). Other rarer histologies include 
small cell carcinoma (aggressive cancers that predominantly occur in younger women with a 
median age at diagnosis of 25 years of age) which have an uncertain tissue origin and 
carcinosarcoma (also an aggressive cancer) (1, 2). Non-epithelial ovarian cancers, including germ 
cell tumours and sex cord stromal tumors which account for approximately 10% of ovarian 
cancers are not discussed in this Primer.  
 
Some ovarian cancers originate from sites outside of the ovary; for example, many ovarian 
HGSCs likely originate in the fallopian tube (3) and some subsets of ovarian cancer have been 
shown to arise from the peritoneum (ref). Also, clear cell and endometrioid carcinomas can 
originate from endometrial tissue located outside the uterus (endometriosis). On the basis of new 
WHO classification, most of these types of ovarian cancer will now be reclassified as ‘ovarian or 
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tubal cancers’ (4).  Indeed, information regarding precursor sites of ovarian cancer has enabled 
the investigation of new primary prevention strategies, such as risk-reducing and opportunistic 
salpingectomy (surgical removal of the fallopian tube) (3). This increased understanding of the 
biology underlying ovarian cancer has also translated to changes in clinical research; clinical 
trials are now increasingly focusing eligibility requirements on the basis of ovarian cancer 
histology.  
 
Effective screening strategies for the early detection of ovarian cancer do not exist, but 
individuals at high-risk of developing ovarian cancer, such as those with germline mutations in 
BRCA1 or BRCA2 (encoding proteins involved in the repair of DNA damage via homologous 
recombination) or other genes associated with high-risk of ovarian cancer, can be identified. For 
these individuals, strategies to reduce ovarian cancer risk have been implemented through risk-
reducing surgery such as bilateral salpingo-oophorectomy (removal of the ovaries and fallopian 
tubes). Screening strategies in women with average risk of developing ovarian cancer have 
primarily focused on the biomarker CA125 (also known as mucin 16) and the use of transvaginal 
ultrasonography. Combinations of these screening modalities have shown success in detecting 
early stage cancers, but have not yet demonstrated definitive improvements in patient mortality 
(6, 7).  
 
The most active therapeutic agents against newly diagnosed ovarian cancer are platinum 
analogues (either cisplatin or carboplatin), with the addition of a taxane (either paclitaxel or 
docetaxel) (8-12). Treatment paradigms for first-line management of newly diagnosed ovarian 
cancer include either primary surgical cytoreduction (to debulk tumours) followed by 
combination platinum-based chemotherapy or neoadjuvant chemotherapy (NACT, administering 
chemotherapy before surgery) followed by interval surgical cytoreduction and additional 
chemotherapy after surgery. Recurrence of cancer after initial platinum-based chemotherapy is 
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very common for women diagnosed with advanced cancer;  is v the most difficult issue in the 
treatment of cancer in these women is the eventual development of platinum resistance. Advances 
in new therapeutics for recurrent ovarian cancer treatment include angiogenesis inhibitors, poly 
(ADP ribose) polymerase (PARP) inhibitors (which block the repair of DNA damage) and 
immunotherapy agents. Strategies using PARP inhibitors as part of the first-line treatment, as 
well as combinations of these therapies for the treatment of both newly diagnosed and recurrent 
ovarian cancer are underway. Overall, the treatment of ovarian cancer based on distinct genomic 
makeup of the individual histological subtypes of ovarian cancer is evolving. 
 
This Primer reviews the epidemiology and known risk factors associated with epithelial ovarian 
cancer, in addition to the molecular biology, diagnostic and prevention approaches and 
management of both newly diagnosed and recurrent cancer. This Primer also discusses patient 
quality of life and concludes with examination of the future outlook for ovarian cancer, including 
new prevention and screening approaches and promising new therapeutic advances. 
[H1] Epidemiology 
 
[H2] Incidence and mortality  
Globally, 225,500 new cases of ovarian cancer are diagnosed each year, with 140,200 cancer-
specific deaths (13-15). Incidence and survival rates vary by country; Russian and the United 
Kingdom have the highest worldwide rates while China has the lowest rates of ovarian cancer 
(ref) . In the United States, approximately 22,280 new cases occur annually and the projected 
number of deaths is 14,240 for 2016 (13). Interestingly, the annual incidence of ovarian cancer 
reduced by 1.09% for women < 65 years of age and by 0.95% for women ≥65 years  between 
1998 and 2008 (ref),  which might have been influenced  by the changing pattern of hormonal 
therapy prescriptions; reduced risk of ovarian cancer coincided with the announcement of causal 
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association between ovarian cancer and use of hormonal replacement therapy and as such, fewer 
prescriptions were written (37). 
 
Over the past decade, minimal improvement in mortality has been observed (14, 15). The US 
Surveillance, Epidemiology, and End Results database reports that overall survival for all patients 
with ovarian cancer is 45.6%, but this varies greatly based on stage at initial diagnosis (16); 5-
year overall survival in patients with stage I cancer is 92.1% but is 25% for patients with stage III 
and IV cancer (13, 16).  
 
[H2] Risk factors  
Several factors can increase the risk of developing ovarian cancer, including genetic factors, age, 
post-menopausal hormonal therapy use, infertility and nulliparity. 
 
[H3]Genetics. A range of genetic factors are associated with an increased risk of developing 
ovarian cancer (Table 2). Germline BRCA1 and germline BRCA2 mutations are the most 
significant known genetic risk factors for ovarian cancer and either mutation is found in up to 
17% of patients (70, 71). Moreover, mutations in BRCA increases the risk of other cancers, such 
as breast cancer,  pancreatic cancer, prostate cancer and melanoma (BRCA2 only) and inheritance 
of these genes have been extensively studied (17-19). Most subtypes of epithelial ovarian cancer 
are associated with germline BRCA mutations, but HGSCs are the most common (17, 18) and 
mucinous subtypes are rarely associated. Survival is improved for women with ovarian cancer 
carrying germline BRCA mutations, compared with women who have ovarian cancer but are 
wild-type for BRCA1 and BRCA2 (19). Germline BRCA2 mutations are associated with increased 
overall survival, compared with germline BRCA1 mutations, likely because BRCA2 results in 
enhanced platinum sensitivity and thus greater cancer cell killing compared with BRCA1 (19, 20). 
Both the location of the BRCA mutation within the gene and the type of the mutation might also 
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influence risk of developing ovarian cancer; the risk of developing breast cancer or ovarian 
cancer, as well as the median age at diagnosis, can vary according to mutation type, nucleotide 
position and the functional consequence of the mutation in patients with germline BRCA1 or 
BRCA2 mutations (21).  
 
Besides BRCA1 and BRCA2, other germline mutations in genes involved in DNA repair can 
increase the risk of developing ovarian cancer, including genes that are part of the Fanconi 
anaemia/BRCA pathway, such as RAD51C, RAD51D, BRIP1, BARD1, and PALB2 (18, 22-25; 
Table 2). Inherited mutations in other genes involved in DNA repair, such as CHEK2, MRE11A, 
RAD50, ATM and TP53, might also increase the risk of developing ovarian cancer (18, 22, 23). 
  
Other inherited disorders, such as Lynch syndrome, can increase the risk of ovarian cancer. 
Lynch syndrome is associated with colorectal, endometrial and ovarian cancers, but can also be 
associated with cancers of the urinary tract, stomach, small intestine and biliary tract. The 
syndrome is characterized by inheritance of a germline mutation in genes of the DNA mismatch 
repair system, namely, MLH1, PMS2, MSH2, or MSH6, which are mutated in differing 
frequencies (26-28). Patients with Lynch syndrome-associated ovarian cancer have a mean age at 
presentation of 48 years (compared with a median age of ~68 years in those without Lynch 
syndrome), with approximately 50% of patients having stage I cancer. Additionally, endometrioid 
and clear cell carcinomas are more common in patients with Lynch syndrome than would be 
predicted for sporadic ovarian cancer (26). Even though both BRCA and the DNA mismatch 
repair pathways are involved in DNA repair, the specific mechanisms are not known why cancers 
arise in specific organs associated with these inherited mutated genes.  
 
[H3] Oral contraceptives and hormone replacement therapy. The use of oral contraceptives 
has been shown to reduce the risk of developing ovarian cancer in individuals with a germline 
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BRCA1 mutation, as well as in those without a genetic predisposition (30, 31). One meta-analysis 
showed a lifetime reduction of 0.54% of ovarian cancer with the use of oral contraceptives for an 
average of 5 years (31) (ref). Interestingly, an analysis from the Ovarian Cancer Cohort 
Consortium (including data from 21 studies, encompassing 1.3 million women and 5,584 ovarian 
cancers) showed that oral contraceptive use was associated with reduction in serous, 
endometrioid and clear cell carcinomas, but not mucinous carcinomas (ref). The relative 
oestrogen and progestin doses in oral contraceptives does not affect the incidence of 
ovarian cancer, but longer duration of oral contraceptive use is associated with reduced 
risk (32). However, other meta-analyses have found insufficient evidence to recommend either 
for or against the use of oral contraceptives to prevent ovarian cancer, given their potential harm 
from adverse vascular events and minimal increase in other cancers (such as breast cancer) 
weighed against the potential for ovarian cancer risk reduction (32).  
Hormone replacement therapy has been shown to increase the risk of developing ovarian cancer 
in post-menopausal women; oestrogen-only therapy increased risk by 22% and the combined 
oestrogen and progesterone therapy increased risk by 10% (33-35). However, a meta-analysis 
showed a similar increase in the risk of developing ovarian cancer, specifically, serous and 
endometrioid carcinomas, in menopausal women using hormone replacement therapy, regardless 
of whether the therapy contained only oestrogen or a combination of oestrogen and progesterone 
(36). Others have confirmed this finding but have also shown a reduced risk of clear cell cancer in 
women using hormone replacement therapy (Wentzensen et al JCO 2016). Interestingly, in 
women diagnosed with ovarian cancer and who also have severe menopausal symptoms, the use 
of hormone replacement therapy appears safe and has no effect on overall survival (38). Thus, use 
of hormone replacement therapy can be considered if patients are having significant menopausal 
symptoms (38).  
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[H3] Reproductive factors. Retrospective studies have identified several other factors that can 
influence the risk of ovarian cancer such as parity, prior tubal ligation, salpingectomy and 
unilateral or bilateral oophorectomy (surgical removal of the ovary) (29, 42,43). Women who 
have given birth have a reduced risk of all subtypes of ovarian cancer, with the strongest risk 
reduction noted for clear cell cancers, compared with women who have not given birth. Unilateral 
oophorectomy is associated with a 30% reduction in the risk of ovarian cancer, which is not 
histological subtype-specific. Bilateral oophorectomy is also effective in reducing risk of ovarian 
cancer in women with a genetic predisposition . Interestingly, 0% of women with a BRCA2 
mutation and 1.1% with a BRCA1 mutation  developed a primary peritoneal carcinoma following 
bilateral oophorectomy (ref). (42). Tubal ligation and hysterectomy are also associated with a 
reduction in the risk of developing ovarian cancer; tubal ligation is associated with reduction in 
risk of clear cell and endometrioid carcinomas and hysterectomy is associated with reduction in 
risk of clear cell carcinoma (Wentzensen et al) (29, 42, 43).In one study, reproductive risk factors 
such as tubal ligation, parity of ≥2, endometriosis and younger age were more strongly associated 
with development of dominant ovarian tumors (meaning one ovarian tumour is at least twice as 
large as the tumour on the other ovary), than with non-dominant cancers which are thought to 
arise in the fallopian tube and are mostly HGSC (44). Also, endometriosis has been associated 
with endometrioid and clear cell ovarian cancer as well as low grade cancers (Wentzensen et al). 
In women with germline BRCA mutations, tubal ligation and breastfeeding have similarly been 
identified as a risk factor associated with a decreased risk of ovarian cancer (29).  
 
[H3] Lifestyle factors. Several studies have identified obesity as a possible risk factor for the 
development of postmenopausal ovarian cancer; one meta-analysis showed an approximate 13% 
increase in risk of ovarian cancer in postmenopausal women with a 5kg weight gain, who did not 
use, or had low use of hormone replacement therapy (45). Moreover, obesity is associated with an 
elevated risk of endometrioid and mucinous carcinomas but not HGSC (ref). However, 
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conflicting data have been reported in other studies (Wentzensen et al). Obesity is also a risk for 
poor outcomes following diagnosis of ovarian cancer; women with obesity and low grade serous 
carcinoma (LGSC), HGSC or endometrioid carcinoma have a worse outcome compared with 
non-obese women (47). Meta-analyses have suggested a beneficial effect of regular physical 
activity on the risk of ovarian cancer, with a 30–60% reduction in risk in the most active women 
(46).  
 
Several studies have examined the association between dietary factors and the risk of developing 
ovarian cancer in the general population. Levels of milk consumption do not confer a significant 
risk for developing ovarian cancer, but one study noted a trend suggesting an inverse association 
between intake of skim milk and lactose in adulthood and risk (49). Moreover, this study showed 
an inverse relationship between lactose intake and the risk of endometrioid carcinoma (49). 
Studies have also assessed the association between other dietary factors, including vitamins and 
flavonoids and risk of ovarian cancer. The intake of folate or vitamins A, C, or E during 
adulthood, or intake of a specific diet (defined by dietary scores) does not alter the risk of ovarian 
cancer (53, 54). Interestingly, flavonoids and black tea might be associated with a reduced risk of 
ovarian cancer, but these require further study (55).  
 
Other lifestyle factors that might affect the risk of ovarian cancer include the use of talc powder 
(reviewed in 52), medications such as NSAIDS and smoking. With respect to talc powder, results 
from case control and prospective studies have been variable; one study showed a modest 
increase in the risk of ovarian cancer, but other studies have shown no increase in risk with talc 
use (50, 51). Aspirin use was associated with a reduced risk of developing ovarian cancer, 
especially among women who took daily, low-dose aspirin, regardless of their age; the same 
associations were not shown for acetaminophen (56). Regular aspirin use was associated with 
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reduced risks of endometrioid and mucinous carcinomas and a significance reduction in 
risk of serous carcinomas. However, no prospective trials testing aspirin for ovarian cancer risk 
reduction have been conducted. Non-aspirin NSAID use was associated with a trend to suggest a 
lower risk of ovarian cancer (56), specifically, of serous carcinomas. Cigarette smoking was 
associated with a significantly lower risk of clear cell carcinoma but an increased risk of 
mucinous carcinoma (Wentzensen et al).  
Finally, data from the Nurse’s Health Study show that persistent depression – defined as 
meeting the definition of depression based on current and past questionnaires – might 
increase the risk of ovarian cancer compared with women who do not exhibit depressive 
symptoms (48)  
 
[H1]Mechanisms/pathophysiology 
The Cancer Genome Atlas (TCGA) project, along with other projects that catalogue genetic 
mutations associated with cancer have produced important molecular data of the different 
histological subtypes of epithelial ovarian cancer (63, 65, 66). These data, in turn, open the 
pathway to improved therapeutic, early detection and risk-reducing strategies. The recognition 
that ovarian cancer is comprised of histologically and molecularly distinct subtypes has 
influenced clinical trial design strategies and patient eligibility and has led to rational clinical 
management (Table 2) (67, 68).  
 
[H2] Molecular alterations  
The best-studied genetic alterations in ovarian cancers are those involved in DNA repair (Figure 
3). Germline or somatic mutations in homologous recombination genes have been identified in 
approximately one third of ovarian carcinomas, including both serous and non-serous histologies 
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and subtypes that were not previously believed to have characteristics of homologous 
recombination deficiency (clear cell and endometrioid carcinoma, in addition to carcinosarcoma). 
As mentioned previously, the commonly implicated inherited genes are BRCA1, BRCA2, 
BRIP1, genes that are part of the Fanconi anaemia pathway (RAD51C, RAD51D, BRIP1, 
PALB2 and BARD1) and genes involved in DNA mismatch repair (MSH2, MLH1, PMS2 
and MSH6). 
 
Despite genomic data showing recurrent mutations in patients with ovarian cancer, some tumours, 
particularly the HGSC subtype, are genetically heterogeneous (63, 66, 76), reflecting the 
underlying genomic complexity of this disease. For example, one study demonstrated intratumor 
genomic heterogeneity in patients with newly diagnosed HGSC (76).  
 
[H3] HGSC. HGSC has been extensively characterized both at initial diagnosis of ovarian cancer 
as well as at disease recurrence after exposure to platinum-based chemotherapy (63, 66).  
TP53 is the most commonly mutated gene in HGSC (63, 66). TP53 mutations can be in-frame 
and frameshift insertions and deletions, as well as missense or nonsense mutations (69). TP53 
mutations frequently occur in the region of the gene encoding the DNA binding domain, but can 
also occur in regions encoding the non-DNA binding domains. Tumours lacking TP53 mutations 
have signs of p53 dysfunction through a copy number gain of MDM2 or MDM4, the gene 
products of which are involved in the regulation and degradation of p53 (69). 
 
Genomic analyses have revealed defects in homologous recombination in approximately 50% of 
analysed HGSCs (70, 71). Defective homologous recombination is associated with both germline 
and somatic BRCA mutations, as well as alterations in other DNA repair pathway genes (Figure 
3) (63). BRCA1 is critical for DNA repair, cell-cycle checkpoint control, mitosis, remodeling of 
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chromatin, and transcriptional regulation; BRCA2 is important in homologous recombination and 
DNA repair (72). Hypermethylation of the BRCA1 promoter has also been shown in a substantial 
subset of HGSCs but does not influence overall survival and outcome (63).  
 
Additional recurrent molecular alterations identified in HGSC include defective Notch, 
phosphoinositide 3-kinase (PI3K), RAS/MEK and FOXM1 pathway signalling, as well as a high 
level of somatic copy number alterations in the genes encoding proteins in these pathways (63). 
Other mutated genes that play a part in the pathogenesis of HGSC and that could also serve as 
potential therapeutic targets for ovarian cancer include AURKA, ERBB3, CDK2, MTOR, BRD4, 
and MYC (63, 77, 78). For example, one study showed that activity of the epigenetic transcription 
modulator, bromodomain-containing protein 4 (encoded by BRD4) is required for the 
proliferation and survival of HGSC cell lines (77). Also, ovarian cancer cells sensitive to BRD4 
inhibition have high expression of MYC, another important gene found altered in HGSC (77).  
 
HGSC has been further subdivided using data from gene expression profiling (79, 80). TCGA 
identified 4 subtypes of HGSC based on gene expression: differentiated, immunoreactive, 
mesenchymal and proliferative subtypes, which have differences in clinical outcome, although 
this has not been clinically useful for patient management (79-81). Attempts to more narrowly 
define the subgroups of HGSC have included integrated genomic analyses incorporating multiple 
platforms. For example, a micro RNA (miRNA)-regulated network was identified that is 
associated with the mesenchymal subtype of HGSC and with poor clinical outcomes (82). Some 
studies have used gene expression profiling to predict the prognosis of patients with advanced-
stage HGSC, in addition to treatment resistance and response to platinum-based chemotherapy 
and PARP inhibitors. However, these studies relied on retrospective analyses and prospective 
data from randomized trials are still needed to show usefulness of expression assays in subtyping 
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patients (83). 
 
The level of molecular diversity of HGSC at the time of diagnosis, its evolution, change over 
time, the presence of few druggable driver mutations and the high rate of copy number alterations 
in genes of multiple signalling pathways characterizes the genomic complexity of this cancer. 
Indeed, this molecular complexity provides insight into perhaps why the development of effective 
therapies for HGSC has been difficult to achieve (63, 66).  
 
[H3] Other epithelial subtypes. The genomic landscapes of other histological subtypes of 
ovarian cancer have also been studied. Clear cell carcinomas are complex at the genomic level 
and can have mutations in ARID1A, PIK3CA and PTEN (94). BRAF and KRAS mutations are 
common in LGSC (95, 96). Also, LGSC mostly exhibits mutational stability such that the extent 
of tumour genetic evolution is low in this cancer type in each patient, but these tumours are 
typically more unresponsive to chemotherapy compared to HGSC (97).  
 
Endometrioid adenocarcinomas frequently carry mutations in PTEN, PIK3CA, and CTNNB1 (98). 
Ovarian cancers associated with endometriosis, such as clear cell and endometrioid carcinomas, 
are associated with ARID1A mutations (98, 99). Low grade endometrioid carcinomas can carry 
loss of PTEN and mutations in PIK3CA and KRAS (98, 100).  
 
Mucinous carcinomas can carry KRAS mutations (102). C>T transitions in an NpCpG 
trinucleotide context have been shown to be the predominant mutational signature of mucinous 
carcinomas, indicating deamination of methylcytosines (103). Approximately half of mucinous 
carcinomas have mutations in TP53 , with other frequent mutations occurring in KRAS, 
BRAF,CDKN2A, RNF43, ELF3, GNAS, ERBB3 and KLF5 (103). 
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Hypercalcaemia-associated small cell carcinomas are associated somatic or germline mutations in 
SMARCA4 (1, 104). 
 
[H2] Precursor lesions  
The distal fallopian tube has been identified as a precursor site of HGSC in a substantial 
proportion of patients due to the presence of atypical tubal epithelial cells in women with BRCA1 
or BRCA2 mutations. This site was identified with the discovery of serous tubal intraepithelial 
carcinoma (STIC) — an early lesion — during risk-reducing bilateral salpingo-oophorectomy in 
these women, with the presence of STICs in the fallopian tubes of women with advanced-stage 
ovarian cancer and with identification of precursors in the fallopian tube characterized by DNA 
damage and mutations in TP53 (3, 59-61, 87, 88, 91). STIC can be identified in 18–60% of cases 
of advanced-stage HGSC (3, 59, 60, 86-88) and up to 80% of early stage HGSC. However, STICs 
are not found in all patients with HGSC and alternative pathways for the pathogenesis of HGSC 
likely exist (89). One study proposed a dualistic model for HGSC pathogenesis that incorporates 
the variables of the patient (for example, presence of STIC, BRCA status, patient age and 
morphological features of the HGSC) (91). The study suggested two pathways of HGSC 
development based on differences in STIC frequency, tumour morphology and outcome, known 
as classic or SET (>50% solid, pseudoendometrioid, or transitional) pathways. The classic 
pathway involves the presence of a STIC precursor and a longer timeframe from STIC to 
development of HGSC. Conversely, the SET pathway typically occurs in younger women, who 
have a lower STIC frequency and higher level of responsiveness to chemotherapy and PARP 
inhibitors. The two pathways of HGSC development might have implications for the potential 
ineffectiveness of risk reducing bilateral salpingo-oophorectomy for some high-risk patients.  
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[H2] Immune system and tumour microenvironment 
Another developing field of research in ovarian cancer pathogenesis is the role of the immune 
system and the tumor microenvironment. Cytotoxic T -cell infiltration in ovarian cancer has been 
shown to correlate with improvement in overall survival in several studies (106, 107). For 
example, antitumor immune responses composed of tumor-reactive T cells and tumour-specific 
antibodies that can be detected in peripheral blood, ovarian cancer tissue and ascites (108-111). 
Furthermore, cytotoxic T cell infiltration in ovarian tumours correlates with improvement in 
overall survival as shown by several groups (106, 107).  
 
Within the many components of the tumor microenvironment, angiogenesis has a critical role in 
the pathogenesis of epithelial ovarian cancer, promoting tumour growth and metastasis (112). 
Vascular endothelial growth factor (VEGF) is one of the most potent proangiogenic factors 
identified in ovarian cancer, with other proangiogenic factors including fibroblast growth factor, 
angiopoietins, endothelins, IL-8, IL-6, macrophage chemotactic proteins and platelet-derived 
growth factors also identified (113, 114).  
 
[H2] Chemotherapy-resistance  
HGSC and other high-grade ovarian cancer histologies, for example high-grade endometrioid 
carcinoma, can be further analysed on the basis of platinum sensitivity. Platinum-sensitive 
ovarian cancers are defined as having a platinum-free interval (PFI; time elapsed between the last 
dose of platinum-based chemotherapy and evidence of cancer progression) of 6 months or 
greater, whereas platinum resistant cancers have a PFI of <6 months. In patients with HGSC, one 
study showed that inactivation of genes by disruption of transcriptional units (gene breakage) can 
inactivate the tumor suppressors RB1, NF1, RAD51B and PTEN, which likely contributes to 
increasing chemotherapy and platinum resistance (66). Upregulation of the ABCB1 gene 
encoding for the drug efflux pump multidrug resistance protein 1 (MDR1) leading to MDR1 
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overexpression could also explain mechanisms of platinum ressitance. Also, germline or somatic 
mutations in BRCA1 or BRCA2 could lead to a favorable treatment response with improved 
responsiveness to chemotherapy (18, 63). Amplification of the 19q12 locus which involves 
CCNE1, (encoding G1/S-specific cyclin-E1, also known as cyclin-E1, which is a cell cycle 
regulator) was associated with primary platinum-resistant and refractory ovarian cancers (66); 
this leads to abundance of cyclin E1, which subsequently activates transcription of BRCA1 and 
BRCA2 , elevating levels of the BRCA proteins and leading to platinum-resistance (63).  
 
[H1]Diagnosis, screening and prevention  
[H2] Diagnosis  
[H3] Clinical presentation. Most women with ovarian cancer are diagnosed in later life, with a 
median age of diagnosis of 63 years (16). Most women are symptomatic at disease presentation 
and have ascites (fluid in the peritoneal cavity) and gastrointestinal dysfunction (for example 
constipation and/or bowel obstruction). Other symptoms at initial presentation include abdominal 
bloating, abdominal and/or pelvic pain, fatigue, gastrointestinal dysfunction (such as nausea and 
vomiting, constipation, diarrhoea and gastrointestinal reflux) and shortness of breath (5). 
Respiratory symptoms can result from extensive intra-abdominal cancer with ascites, causing 
diaphragmatic pressure, pleural effusions and/or a pulmonary embolus.  
 
Symptoms of ovarian cancer might be initially missed or attributed to other disease processes 
because they are general and non-specific. Accordingly, diagnosis frequently occurs when the 
cancer has reached a late stage (either stage III or IV), because symptoms have become apparent 
and require intervention (5), and/or the symptoms are more-severe, indicative of extensive 
peritoneal carcinomatosis (cancer of the peritoneum), ascites, and the possible bowel involvement 
of cancer. The combination of abdominal bloating, increased abdominal size and urinary 
symptoms has been found in 43% of patients with an eventual diagnosis of ovarian cancer but 
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only in 8% of patients not diagnosed with ovarian cancer (115). Women presenting with severe or 
frequent symptoms and those of recent onset warrant further diagnostic investigation because of 
the association of these symptoms with ovarian masses (155).  
 
Importantly, these symptoms — and their late presentation — largely apply to those with HGSC. 
By contrast, histologies such as clear cell and small cell carcinoma can become symptomatic at an 
earlier stage. For example, hypercalcaemia can be the initial presentation of clear cell or small 
cell carcinomas. These tumour types are also associated with many of the same symptoms 
observed with more advanced HGSC, such as abdominal distension, pelvic pressure and/or pain, 
as well as pressure of the ovarian mass on the bowel or urinary tract system. Most patients with 
clear cell carcinomas present at an early stage and might present with symptoms related to pelvic 
pressure.  
 
[H3] Diagnostic work up. In patients with indicative symptoms diagnostic work up includes 
physical examination of the patient, consisting of pelvic examination and recto-vaginal 
examination, in addition to radiographic imaging (transvaginal ultrasonography, abdominal 
ultrasonography, CT, MRI and/or PET (Figure 2)). The CA125 blood test can also be used in 
combination with other diagnostic tests for the detection of ovarian cancer. Laparoscopic surgery 
with removal of the mass is recommended (116) and will also give further information on the 
tumor histology. Results from diagnostic testing, especially transvaginal ultrasonography, can 
give information regarding the ovarian mass such as size, location and level of mass complexity, 
which can help clinicians determine the level of suspicion for cancer (ref). More advanced cancer 
is associated with ascites and peritoneal carcinomatosis within the abdominal cavity; in order to 
confirm a diagnosis of ovarian cancer, a tissue biopsy must be performed.  
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[H3] Staging. Pathological evaluation and tumour staging of ovarian cancer is based on surgical 
assessment of the cancer at initial diagnosis, including removal of lymph nodes, tissue biopsy and 
abdominal fluid and uses the International Federation of Gynecology and Obstetrics (FIGO) 
staging system (Table 3). The staging system has recently changed with acceptance of the 
common, Müllerian-derived multicentric origin of ovarian, fallopian tube and peritoneal cancers 
and that these cancers should be grouped using one system (127). The latest FIGO staging system 
has three other notable characteristics: stage IC tumours have been subdivided based on the 
mechanism underlying rupture of the ovarian capsule and the presence of malignant ascites (the 
presence of tumour cells in ascites), stage IIC has been eliminated and stage III has a clearer 
definition that encompasses the size of metastases as well as the presence of metastases to the 
lymph nodes. Moreover, stage III was reclassified to account for differences in the clinical 
outcomes in patients with metastases to the lymph nodes who do not have peritoneal 
carcinomatosis, versus patients with peritoneal carcinomatosis (128, 129). Additionally, stage IV 
has been further divided into stage IVA, and IVB. The FIGO staging system recommends that the 
primary tumour site (the ovary, fallopian tube or peritoneum) and the histological grade be stated 
in either the operative report and/or the final pathology report (127).  
Surgical staging of ovarian cancer by gynaecological oncologists has been shown to be superior 
to that performed by non-oncological (general) surgeons as have patient outcomes (138–140). 
Indeed the issue with accurate staging is pertinent; one study found that only 54% of women with 
ovarian cancer received correct staging as determined by a gynecologic oncologist (141). When 
patients are operated by non-gynecologic oncologists, such as general surgeons or general 
gynecologists, the diaphragm was not visualized in 86% of cases and the omentum was not 
biopsied in 68% of cases (141), meaning cancer was commonly missed in the diaphragm, pelvic 
peritoneum, peritoneal fluid and omentum. 
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[H2]Screening 
No current screening strategy has affected survival of patients with ovarian cancer. Creation of a 
successful screening strategy for ovarian cancer is challenging because this is not a common 
disease and includes a range of histological subtypes, each with different biological and clinical 
properties. For example, patients with LGSC have substantially better overall prognoses than 
patients with more-aggressive, high grade cancers and might require a different screening strategy 
(95).  
 
The CA125 blood test is not an effective screening test when used alone, given that CA125 is 
only elevated in 50% of stage I ovarian cancers and can also be increased in benign disorders 
such as uterine fibroids, ovarian cysts and other conditions such as liver disease and infections 
(117, 118). CA125 elevation is most frequently observed in HGSC, with lower levels of CA125 
in other non-serous subtypes (ref). 
Combining the CA125 blood test and radiographic imaging, such as transvaginal 
ultrasonography, has been evaluated for use as a screening strategy. One of the largest studies to 
examine this combination was the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer 
Screening Randomized Controlled Trial (120), which enrolled 78,216 women between the ages of 
55–74 years. Women were randomly assigned into two groups of approximately equal size, to 
receive either annual screening (encompassing yearly CA125 tests for 6 years and transvaginal 
ultrasonography for 4 years) or usual care (no yearly CA125 or transvaginal ultrasound, but could 
have undergone bimanual examination with ovarian palpation). Ovarian cancer was diagnosed in 
212 women (5.7 per 10,000 person-years) in the screening group and in 176 women (4.7 per 
10,000 person-years) in the usual care group (rate ratio 1.21; 95% CI=0.99–1.48) (5) and the 
stage distributions of cancer were similar for the two groups (stage III and IV cancers comprised 
almost 80% of cancers in both groups). Also, no significant reduction in overall mortality was 
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observed with screening (3.1 deaths per 10,000 women in the screened group and 2.6 deaths per 
10,000 person-years in the usual care group; mortality rate ratio of 1.18 (95% CI= 0.82–1.71)) (5)  
 
Although the CA125 tested alone as a screening marker has been deemed ineffective, the UK 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) study evaluated the strategy of 
longitudinal measurements of CA125 levels has also been assessed for screening of ovarian 
cancer, in an algorithm termed ‘risk of ovarian cancer algorithm’ (ROCA) (5, 7,123). In one arm 
of this study, ROCA was the primary screening modality with transvaginal ultrasonography used 
as a secondary screening measure based on CA125 levels (7). The ROCA algorithm interpreted 
longitudinal CA125 data and triaged women to either normal (annual screening), intermediate 
(repeat CA125 testing in 3 months) and elevated risk (repeat CA125 testing and transvaginal 
ultrasonography in 6 weeks). Annual screening used transvaginal ultrasonography as the primary 
test, following which, patients were subdivided into 3 groups based on ultrasonography results; 
normal (annual screening), unsatisfactory (repeat in 3 months) and abnormal (scan with a senior 
ultrasonographer within 6 weeks). In this study, 202,638 women were randomly assigned into one 
of three groups (screening based on the ROCA algorithm, ultrasonography alone and no 
screening) (7) and followed-up for a median period of 11.1 years. The proportion of women 
diagnosed with ovarian cancer was similar between groups (between 0.6–0.7%), but lower stages 
(stage I-IIIA) of disease was in a higher proportion of patients in the ROCA screened group than 
in those who were not screened (P <0.0001). However, there was no difference between patients 
in the ROCA group and those who received transvaginal ultrasonography (P=0.57). Mortality 
reduction was not significant between any of groups, therefore, the ROCA test cannot currently 
be recommended as a screening strategy for ovarian cancer; further follow-up of this study is 
necessary to understand the long-term potential of this screening strategy.  
 
WAP four-disulfide core domain protein 2 (also known as human epididymis protein 4 (HE4)) 
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has also been tested as a potential biomarker for use in ovarian cancer screening (124). A 
systematic review reported better sensitivity, specificity and likelihood ratios for HE4 compared 
with CA125, but this has not yet been analysed within a screening strategy (125). The use of 
other novel markers for ovarian cancer screening are under investigation, including, for example, 
DNA analysis of uterine lavages or Pap smears for TP53 mutations (126).  
 
[H2] Prevention 
Salpingectomy has gained favour as a prevention technique based on the presence of precursor 
lesions in the fallopian tubes of some women with ovarian cancer as discussed above. However, 
no randomized prospective studies have been performed to determine the benefit or evidence of 
risk reduction following salpingectomy (39-41).  
 The Society of Gynecologic Oncology guidelines and recommendations for the prevention of 
ovarian cancer. These guidelines, in addition to others, recommend all women with invasive 
ovarian cancer (regardless of family history, histology or age) should undergo genetic testing and 
genetic counseling. The purpose of this testing is to assess women for the presence of a high risk 
gene which could convey increased risk for both the individual and family members, as well as 
having implications for outcome and therapeutic management (57, 58). Moreover, the Society of 
Gynecologic Oncology guidelines recommend performing risk-reducing bilateral salpingo-
oophorectomy in women aged 35–40 years who are at increased genetic risk (the presence of 
germline mutations in high risk genes) of developing ovarian cancer, as well as individualizing 
the age at which women undergo risk-reducing surgery (57). Also, the Society of Gynecologic 
Oncology guidelines mandate and recommend microscopic examination of the entire ovary and 
fallopian tube following risk-reducing bilateral salpingo-oophorectomy in high-risk women, to 
rule out early invasive cancers (57, 59-61).  
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The annual risk of ovarian cancer in individuals of specific age groups with germline BRCA 
mutations and intact ovaries has been estimated, to help guide clinicians and patients about 
appropriate timing of the risk-reducing bilateral salpingo-oophorectomy (62). In one study, risk-
reducing salpingo-oophorectomy reduced risk of ovarian cancer in women with BRCA mutations 
by 80%. Timing of risk-reducing bilateral salpingo-oophorectomy is important, as performing 
surgery in women < 45 years of age has been associated with an increased risk of cardiovascular 
disease, osteoporosis and osteopenia (57); oestrogen replacement should be considered in these 
patients (if they have not had breast cancer), but the benefits and potential risks or optimal 
duration of oestrogen therapy has not been determined (57). 
Variants of unknown importance occur in BRCA1 and BRCA2, as well as other high risk genes 
implicated in ovarian cancer, but the effects of these variants on ovarian tumorigenesis are 
currently unknown (75). Variants of unknown importance represent dilemmas for women who 
are diagnosed with them, as these variants carry an unknown cancer risk, meaning patients and 
their family members cannot be accurately counseled about risk reduction and preventative 
surgeries.  
 
[H1]Management  
At initial diagnosis, patients are faced with the challenge of accessing appropriate medical 
treatment and quickly making complex decisions about their care. The choice of physician can 
impact outcomes (130, 131) as can adherence to the guidelines for the standard of care (132, 
133); surgery performed by a gynecologic oncologist results in superior outcomes and survival, 
compared with surgery performed by a non-gynecologic oncologist, such as a general surgeon.  
The primary aim of treatment for ovarian cancer is to maximize cancer control and to palliate 
disease symptoms for as long as possible. Surgery performed by a gynecologic oncologist is the 
main treatment for most patients with ovarian cancer. The extent of surgery is determined by the 
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stage of cancer and patient factors; for example, women with more advanced cancer might 
undergo bilateral oophorectomy, but women with low risk, stage I cancer (such as mucinous 
histologies) and young women who wish to preserve fertility, might undergo unilateral 
oophorectomy of the affected ovary only. Surgical cytoreduction results are frequently referred to 
as suboptimal (meaning any focus is ≥1cm in size, R2 resection), optimal (meaning <1 cm 
residual cancer, R1 resection) or no evidence of residual macroscopic disease (R0 resection). 
New studies only define optimal surgical results if macroscopic complete resection of the cancer 
has been achieved. Patients with macroscopic complete resection (R0) following surgery have 
significant improvements in outcomes, such as overall survival and progression-free survival 
(PFS), compared with patients with remaining post-operative visible disease (135, 136). For 
example, in one study (GOG 182) patients with stage III or IV ovarian cancer with optimal 
cytoreduction had a worse prognosis than patients with no evidence of residual macroscopic 
disease or R0 followed by platinum-based chemotherapy. Nevertheless, patients with optimal 
cytoreduction have a significantly better median PFS and overall survival than patients with 
suboptimal cytoreduction (134-136). 
 
[H2]Newly diagnosed ovarian cancer 
 
[H3] Primary surgery. The primary treatment for women with newly diagnosed ovarian cancer 
is primary surgical cytoreduction (Figure 4). The primary goal of surgery is to achieve 
macroscopic complete resection of disseminated carcinomatosis, often involving complex 
surgical techniques, including en bloc resection of the bowel, uterus and adnexal masses, as well 
as peritonectomy. In some cases, colonoscopy and/or upper endoscopy might be required, to rule 
out the possibility of a primary gastrointestinal cancer, rather than a primary ovarian cancer. 
Systematic pelvic and paraaortic lymph node dissection is also necessary in patients with high-
risk early stage ovarian cancer, or patients with stage II and IIIA disease, because nodal 
metastases signify a higher stage of disease, poorer prognosis and the need for different treatment 
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strategies. 
It is critical for the surgeon to define the best surgical approach and determine the appropriateness 
of surgery prior to administration of chemotherapy versus NACT. If NACT is to be administered, 
a biopsy is needed to confirm pathology consistent with an ovarian, tubal or peritoneal primary 
cancer, before chemotherapy can be commenced. 
 
[H3] Adjuvant chemotherapy. Recommendations for the use of adjuvant chemotherapy using 
platinum-based chemotherapy for patients with early stage ovarian cancer depend on cancer 
stage, grade and histology. Many patients with grade I, stage I cancer are not treated with 
chemotherapy post-surgery but those with higher grades (≥ grade II) and/or specific histologies 
(such as HGSC and clear cell carcinomas) undergo adjuvant systemic platinum-based 
chemotherapy (142). Indeed, several first-line adjuvant systemic chemotherapy strategies have 
led to an improvement in overall survival for patients with newly diagnosed, advanced-stage 
ovarian cancer including the addition of paclitaxel to platinum-based chemotherapy agents, use of 
intraperitoneal cisplatin in patients with optimally cytoreduced cancer and incorporation of dose-
dense weekly paclitaxel treatment instead of administration every 3 weeks (7, 143-145). 
Studies have examined the efficacy of different combinatorial treatments to optimize adjuvant 
chemotherapy, including combinations of platinum-based chemotherapy agents (cisplatin and 
carboplatin), taxanes (paclitaxel, docetaxel), anti-angiogenic agents (bevacizumab, nintedanib, 
trebananib and pazopanib) and other drugs (pegylated liposomal doxorubicin, gemcitabine) 
(Table 4).  
In 2011, the European Medicines Agency (EMA) approved the use of bevacizumab as an addition 
to carboplatin/paclitaxel chemotherapy and maintenance therapy in patients with newly 
diagnosed, advanced-stage ovarian cancer, based on the improvement in PFS in the GOG218 and 
ICON7 studies (Table 4). A retrospective analysis of the ICON7 study of patients with 
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suboptimally cytoreduced stage IIIC or stage IV cancer showed an overall survival benefit with 
the addition of bevacizumab to a carboplatin/paclitaxel backbone, but no improvement in overall 
survival was observed in the intent to treat population of patients entered in either ICON7 or 
GOG 218 (151-153). Despite being available in Europe, bevacizumab has not been approved for 
patients in the United States, making collaborative trial design for both newly diagnosed and 
recurrent ovarian cancer challenging.  
[H3] Neoadjuvant chemotherapy. NACT consisting of carboplatin and paclitaxel for 3 cycles is 
then followed by interval (meaning between rounds of chemotherapy) surgical cytoreduction and 
additional chemotherapy post-surgery for a total of 6 cycles of chemotherapy. NACT is a possible 
treatment alternative to upfront surgical cytoreduction for ovarian cancer, especially for patients 
who are too ill for initial surgery or if the cancer burden is too extensive to allow macroscopic 
complete resection. Two trials have demonstrated comparable outcomes for first-line surgery with 
adjuvant chemotherapy, compared with NACT followed by surgery and post-operative 
chemotherapy, with less morbidity and mortality but similar outcomes in PFS and overall survival 
in the group that received NACT (160, 161). Data from the first study showed NACT followed by 
interval cytoreductive surgery is not inferior to primary cytoreductive surgery followed by 
chemotherapy and no significant difference in PFS (12 months) or overall survival (29–30 
months) was found between groups (160). The second study (CHORUS) in patients with 
advanced stage III or IV cancer randomly assigned to either primary cytoreductive surgery 
followed by chemotherapy (consisting of either carboplatin and paclitaxel or carboplatin alone), 
or to NACT (3 cycles), followed by cytoreductive surgery and three more cycles of chemotherapy 
(carboplatin and paclitaxel or carboplatin alone) showed a non-significant difference in overall 
survival between the group that received NACT (24.1 months) and those that received upfront 
surgery (22.6 months; 95% HR 0.87, 95% CI 0.72–1.05) (161). Additionally, PFS was similar for 
both groups; 12.0 months in the NACT group, compared with 10.7 months for the primary 
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surgery group (HR 0.91, 95%CI: 0.76–1.09). However, the number of post-operative deaths was 
lower in the NACT group compared to the upfront surgery group (161). 
 
Some medical centres are testing the use of surgical algorithms with diagnostic laparoscopy to 
determine tumour resectability, to identify patients who are appropriate for first-line 
cytoreductive surgery, versus those suitable for NACT, but no validated preoperative instrument 
has currently been established (162). Controversy persists over the identification of the most 
appropriate candidates for NACT and whether NACT induces upfront platinum resistance. 
Accordingly, a general consensus regarding the equivalence of NACT followed by surgery and 
upfront surgery followed by adjuvant chemotherapy is lacking (163). Also, some groups have 
argued that the overall survival and PFS outcomes used in the aforementioned randomized trials 
of NACT versus upfront surgical cytoreduction (160, 161) are inferior to other trials and that 
inferior complete resection rates were observed in the primary surgery control group, particularly 
in the CHORUS study (164, 161).  
 
[H3] Maintenance therapy following NACT. Aims of maintenance therapy are to prolong a 
clinically meaningful survival endpoint, such as PFS and also preserve a patient’s quality of life. 
The use of maintenance therapy following platinum-based chemotherapy has been investigated 
and reviewed (165, 166). Monthly paclitaxel treatment (for a duration of either 3 months or 12 
months) has been assessed in patients with ovarian cancer following completion of NACT (167); 
no benefit in overall survival was observed with 12 month paclitaxel treatment, compared to 
treatment for 3 months, but PFS was longer in the 12-month versus 3-month groups. However, 
due to the risk of developing adverse effects with continuation of monthly paclitaxel for 12 
months (for example, alopecia and peripheral neuropathy), the use of paclitaxel for maintenance 
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therapy after platinum-based chemotherapy is not commonly used; currently, the standard of care 
following completion of platinum-based chemotherapy is observation alone (142).  
Pazopanib has also been studied for use in maintenance therapy, resulting in an increase in PFS, 
but no improvement in overall survival (156). Pazopanib is also associated with a significant 
toxicity profile such as fatigue, gastrointestinal toxicities (such as nausea and/or diarrhoea), 
hypertension and myelosuppression (156). 
Bevacizumab is approved in Europe as maintenance therapy following initial 
platinum/taxane/bevacizumab chemotherapy based on GOG218 and ICON7 results.  
 [H2]Recurrent disease 
[H3] Monitoring for recurrence  
 >80% patients with advanced-stage ovarian cancer will experience recurrence of their primary 
cancer. Recurrent ovarian cancer is generally incurable, but rare exceptions to this exist, such as 
patients with isolated metastatic cancer in whom the disease can be fully resected after secondary 
cytoreductive surgery or treatment with localized radiotherapy.  
Many patients with recurrent ovarian cancer are asymptomatic at the time of their relapse and as 
such, recurrent ovarian cancer is most frequently detected by elevation of CA125 levels; the 
sensitivity and specificity of this test for recurrence detection range from approximately 60–94% 
and 91–100%, respectively (168, 169). CA125 levels are monitored following completion of 
initial treatment, but guidelines regarding the frequency of CA125 and clinical monitoring of 
patients with ovarian cancer changes with differing guidelines (168, 169). The Society of 
Gynecologic Oncology recommends a review of clinical symptoms and a physical examination of 
patients following initial treatment for ovarian cancer every 3 months with an optional CA125 
test and radiographic imaging (CT, PET or MRI) in patients with suspected recurrence (such as 
those with an elevated CA125, findings upon clinical examination and/or suspicious symptoms) 
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(169). Conversely, the National Comprehensive Cancer Network guidelines recommend follow-
up visits every 2–4 months for 2 years after treatment, including assessment of CA125 levels and 
radiographic imaging if recurrence of ovarian cancer is indicated (142).  
The limitations of disease detection and the role of CA125 should be discussed with all patients 
who have completed therapy. Sufficient clinical information should be available to make a 
definitive diagnosis of cancer recurrence, including elevated CA125 levels, radiographic evidence 
of cancer, physical exam evidence, symptoms related to the disease burden and/or a positive 
biopsy. Elevated CA125 in the absence of other clinical indicators is generally not a reason to 
initiate treatment, unless the patient is enrolling into a clinical trial. Some patients might not have 
elevated CA125 levels at either initial diagnosis or with recurrence of ovarian cancer, which 
makes the CA125 test less useful when used for recurrent cancer. In these patients, alternative 
biomarkers, such as HE4 and/or the use of interval radiographic imaging might be of use for 
monitoring of recurrent cancer, but this needs further evaluation. Although used, CA125 for the 
early detection of recurrence has not been shown to improve outcomes in patients with recurrent 
disease. In one study, no improvement in patient survival was observed following early treatment 
of recurrent ovarian cancer (diagnosed on the basis of increased CA125 levels in the absence of 
clinical symptoms), compared with delayed treatment (until the manifestation of clinical 
symptoms of disease progression) (170). This trial has been criticized because of the long period 
of time needed to accrue patients (almost 10 years), the lack of predefined subsequent therapies 
and the lack of access to newer treatments (such as bevacizumab) and other drugs through clinical 
trials, or to the potential use of secondary cytoreductive surgery (ref).  
 
[H2]Treatment options  
Following definitive diagnosis of recurrent ovarian cancer, several factors should be considered 
before deciding appropriate treatment options, including the level of disease burden (such as, 
symptomatic versus asymptomatic cancer and the location of metastases), the presence of 
 30 
complications from previous therapies (such as peripheral neuropathy, pancytopenias and/or drug 
hypersensitivity reactions), availability of clinical trials, degree of platinum sensitivity, end organ 
function, performance status of the patient and also, wishes and goals of the patient. Treatment of 
recurrent ovarian cancer has been made more complex, with oncologists factoring in tumour 
histology and underlying BRCA status, given the recent FDA and EMA approvals of the PARP 
inhibitor olaparib. 
 
Secondary surgical cytoreduction can be considered for patients with a long platinum free interval 
with recurrent cancer that is limited and isolated, such as cancer in one location such as the spleen 
or an isolated lymph node, although meta analyses did not demonstrate any benefit of this surgery 
(172). One randomized trial (GOG 213) investigating the efficacy of secondary surgical 
cytoreduction for the treatment of platinum-sensitive recurrent ovarian cancer is underway (171). 
The German AGO Study Group (Arbeitsgemeisnchaft für Gynäkologische Onkologie) has 
demonstrated a potential survival benefit only in patients with no postoperative residual cancer 
following secondary cytoreductive surgery (173). This study also established a preoperative 
clinical score to predict the target population with the best outcomes following secondary 
cytoreductive surgery including the amount of ascites (<500ml) and result of primary surgery 
(macroscopically free). On the basis of these findings, a prospective study was conducted 
comparing the overall survival of patients with platinum-sensitive recurrent ovarian cancer 
undergoing cytoreductive surgery followed by platinum-based chemotherapy, with patients 
receiving chemotherapy alone (DESKTOP-Trial III), results of which are expected in 2017 (174).  
Recurrent ovarian cancer is classified as platinum-sensitive or platinum-resistant as defined 
above. However, the Institute of Medicine called for an improved classification system for 
recurrent ovarian cancer, as the current classification does not reflect the effect of BRCA status on 
treatment responses and the varied responses to treatment in women with platinum-resistant 
 31 
cancer (179). Additionally, some groups have called for diminishing the importance of the PFI as 
this definition is flawed, with no universally accepted objective definition and instead, 
incorporating key disease parameters such as molecular signature (such as BRCA mutation), 
immunological features and tumor histology (178).  
 
[H3] Platinum-sensitive disease. For patients with platinum-sensitive recurrent ovarian cancer, 
the standard of care is re-use of a platinum-based regimen (142). However, re-use of platinum-
based chemotherapy is associated with the development of potentially life threatening platinum 
drug allergies (177). Response rates in patients with platinum-sensitive recurrent cancer are 
approximately 50% (142, 180-182), although the length of the PFI decreases with subsequent 
platinum use (ref). Various combinations of therapies are being investigated for the treatment of 
platinum-sensitive ovarian cancer (Table 5), including paclitaxel/carboplatin (180), carboplatin 
/pegylated liposomal doxorubicin (181) and carboplatin/gemcitabine (182). Use of a platinum 
based combination has been shown to improve outcomes compared with the use of single agent 
platinum in patients with a platinum sensitive recurrence (ref)  
 
Approved therapies for the treatment of patients with recurrent, platinum sensitive ovarian cancer 
in Europe include bevacizumab (in combination with carboplatin and gemcitabine) and 
trabectedin (an agent that binds to DNA, resulting in cell cycle arrest and apoptosis) (182). 
Carboplatin and gemcitabine are approved for use in the United States. Trabectedin was not 
ultimately approved for use in the United States due to toxicity concerns; adverse effects of this 
agent include bone marrow suppression, fatigue and gastrointestinal complications (such as 
nausea, vomiting and diarrhoea), in addition to elevation of liver enzymes. 
Olaparib has been approved by the EMA as a maintenance therapy for platinum-sensitive ovarian 
cancer, after response and completion of platinum-based chemotherapy in patients with either a 
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germline or tumour BRCA mutation. However, accelerated approval for olaparib as a maintenance 
therapy in patients with germline BRCA mutations was rejected by the FDA’s Oncologic Drugs 
Advisory Committee, due to a lack of evidence supporting improvements in overall survival; the 
final results of a confirmatory phase III study (SOLO2) will likely factor into future FDA 
decisions (203, 204). Nonetheless, the FDA granted accelerated approval to olaparib as a single 
agent for use in patients with germline BRCA mutations who have received at least three prior 
lines of chemotherapy, regardless of platinum sensitivity (205).  
 
[H3] Platinum-resistant disease. For patients with platinum-resistant cancer, bevacizumab with 
weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan treatment in the first platinum-
resistant setting was approved by both the FDA and EMA, following the results of the AURELIA 
trial (187, 188). Although promising, care should be taken when using bevacizumab in patients 
with ovarian cancer, due the risk of severe adverse effects, such as gastrointestinal perforation 
(189), hypertension, proteinuria and fistula development. Other single agents available to treat 
platinum-resistant ovarian cancer include gemcitabine, etoposide and navelbine (142), which 
have response rates of up to 10-15% and median PFS of approximately 3-4 months. 
Anti-angiogenic agents that have been studied in recurrent ovarian cancer include nintedanib, 
trebananib, sunitinib, cabozantinib, and cediranib (190, 191). Notably, cediranib has single agent 
activity in both platinum-resistant and platinum-sensitive recurrent ovarian cancer (192), can 
increase PFS when combined with platinum-based chemotherapy and can also be used as 
maintenance therapy in patients with platinum-sensitive recurrent cancer (185). Also, cediranib is 
being tested in combination with olaparib in two actively accruing phase III studies, GY004 and 
GY005 (193 and 194).  
Ultimately, treatment of recurrent ovarian cancer should be tailored to the patient to prevent 
worsening of pre-existing adverse effects such as myelosuppression and neuropathy, as well as 
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respecting the patient’s wishes and the avoidance of other adverse effects such as alopecia and 
gastrointestinal complications.  
 
 
[H1]Quality of life 
The diagnosis of any life threatening disease, coupled with the acute and long-term adverse 
effects of treatment, can be associated with reductions in quality of life domains, including 
physical, functional, emotional, sexual, social and occupational well-being. Moreover, the large 
number of medical decisions required in a short period of several days to weeks following initial 
diagnosis of ovarian cancer can add to the emotional stress felt by patients. The responses to these 
issues varies; for example, some patients might re-evaluate their attitudes to relationships, work 
and day-to-day life following a diagnosis of ovarian cancer (220).  
 
Although current treatment advances give more women with ovarian cancer the prospect of living 
longer, minimizing and/or ameliorating the adverse effects associated with treatments is crucial if 
quality, as well as length, of life is to be improved. Improvements in PFS or overall survival in 
trials might excite clinical scientists, but be of less value to patients experiencing treatment-
related adverse effects; because of this, many phase III studies have incorporated standardized, 
validated quality of life measures (commonly referred to as patient reported outcome (PRO) end 
points) into studies (221, 223). PROs are important as there are increasing doubts raised about the 
validity of data regarding adverse events collected during clinical trials; several studies have 
shown that the symptoms of disease and adverse effects of treatment are often under-recognized, 
under-reported and consequently under-treated (224). Indeed, patients report adverse effects (such 
as fatigue, nausea, vomiting, constipation, alopecia, appetite loss and pain) occur earlier, more 
frequently and of greater severity than do clinicians and nurses using Common Terminology 
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Criteria for Adverse Events (CTCAE) grading or proxy raters (224). 
 
Quantification of quality of life issues faced by women with ovarian cancer requires well-
constructed, reliable PRO measures that need to be essential components of phase III studies. 
Both the FDA and EMA have clear guidelines on PRO instruments that are acceptable for 
conducting health technology assessments, defined as outcomes reported by patients, without the 
intervention of a third party and that have been constructed using appropriate psychometric 
methodology (225). One key issue is that the PRO measures should be defined upfront and during 
trial development, with patients involved in their production. PRO measures used for ovarian 
cancer include generic, tumor-specific, treatment-specific or symptom-specific measures (226, 
228, 229) and involve face-to-face interview schedules (230), quality of life questionnaires (227-
229, 231, 232), satisfaction scales and patient preference approaches (233).  
For example, a PRO might include a series of questions related to the severity of various 
symptoms, such as lack of energy, pain, discomfort, sexual dysfunction, feeling ill, insomnia, 
sweating, bowel control and constipation, as used in the GY004 trial.  
 
Thorough monitoring using validated instruments within clinical trials is needed to compile a 
database of the trajectory and severity of issues such as adverse effects of treatment, in addition to 
emotional distress, permitting better evaluation of the benefits and harms of therapies, but also to 
establish the case for more research to develop therapies to reduce the adverse effects. The 
traditional end points of clinical trials (such as PFS and overall survival) need to be integrated 
with PROs in order to improve quality as well as quantity of life.  
 
[H1] Outlook 
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Now is a very exciting and promising time for ovarian cancer research, yet challenges remain in 
early detection, identification of women who are at higher risk of developing ovarian cancer, 
overcoming platinum resistance and resistance to other treatments, in addition to developing 
rationale and effective immunotherapeutic strategies.  
With the fields of genomics yielding more genetic information about ovarian cancer, in addition 
to the genotype of patients and with costs of sequencing dropping, understanding the 
pathophysiology and rationale design of therapeutics are poised to move forward. In fact, the 
National Comprehensive Cancer Network genetics guidelines as well as several European 
organizations have recommended universal germline BRCA mutation screening for all women 
diagnosed with ovarian cancer, in order to identify family members at high risk and the risk of the 
patient developing other cancers besides ovarian cancer, to allow performance ofrisk reducing 
surgeries . Moreover, the extent of genetic testing, including panel testing that includes genes 
other than BRCA1 and BRCA2, continues to evolve and will contribute to our understanding of 
the genetics underlying formation of ovarian cancer and its biology. Improved understanding of 
the genomics of different histological subtypes of ovarian cancer will be an important target over 
the upcoming years, to facilitate the understanding of the risk factors associated with this disease, 
as well as development of prevention and therapeutic strategies.  
Early detection efforts are promising, with ROCA testing demonstrating increased detection of 
early ovarian cancers, compared with no testing. However, results of the UKCTOCS study did 
not show an overall survival advantage to using the ROCA thus no screening test exists at this 
time. Additionally, further research elucidating the role of variant of unknown importance in both 
BRCA genes and in other associated genes (such as BRIP1 and RAD51) in the risk of developing 
ovarian cancer is critical for the appropriate recommendation of risk-reducing surgeries.  
 
Other risk reducing efforts, including surgical techniques such as bilateral salpingectomy, that are 
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not directed at the high risk population but more at a general risk population are ongoing. 
Understanding the pathogenesis of the various types of ovarian cancer, such as the precursor 
STIC lesions for HGSC, is critical for the appropriate use of surgical interventions for prevention 
of ovarian cancer. Establishing uniform criteria for the definition of the site of origin of HGSC, 
based on specific pathology findings, is being called for by consensus statements (93).  
 
[H2] Emerging therapies 
Promising future therapies for ovarian cancer include PARP inhibitors and antibody–drug 
conjugates. PARP inhibitors, initially olaparib, have shown single agent response rates of up to 
30% in recurrent ovarian cancer with the greatest activity in cancers with BRCA mutations and in 
platinum-sensitive disease (197-199). Other PARP inhibitors (such as niraparib, rucaparib, and 
veliparib) that have single agent activity in ovarian cancer, are in phase III studies of, for 
example, use as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer, 
following a response to treatment with platinum-based chemotherapy (206, 207) (Table 6); 
rucaparib was recently given breakthrough status (to accelerate the development and review of 
the drug) by the FDA based on results from the ARIEL2 trial (208). Veliparib has been added to 
the NACT armamentarium with carboplatin and paclitaxel for newly diagnosed advanced ovarian 
cancer in a phase III study, in addition to testing as a maintenance therapy (209).  
Acknowledging that the effectiveness of single agent biologic therapies has reached a therapeutic 
plateau, one promising approach has been the development of combinations of biological agents 
(anti-angiogenics, PARP inhibitors, and immunotherapy agents) (236, 237, 241, 242). Such a 
strategy would target multiple cancer-promoting pathways or mechanisms and might be effective 
in particular in HGSC due to its genomic complexity. Other histological subtypes such as clear 
cell carcinoma that can harbor deficiencies in homologous recombination, such as mutations 
ARID1A and PIK3CA, might also be clinically responsive. Furthermore, biologic combinations 
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have the advantage of including agents that have non-overlapping adverse effects that might 
potentially reduce treatment-related toxicities.  
 
Combining PARP inhibitors with targeted therapies against the PI3K pathway is being 
investigated, based on pre-clinical evidence from patient-derived xenograft models. 
Combinations of PARP inhibitors and, for example, CDK inhibitors, immunotherapy agents and 
HSP90 inhibitors (239, 240) are also being assessed. Combining PARP inhibitors with 
chemotherapy has already proved challenging due to overlapping myelosuppression associated 
with both therapies.  
 
Study of immunotherapy strategies for treatment of recurrent ovarian cancer is underway (213) 
with several immune checkpoint inhibitors tested in recurrent disease (Table 6). At this time, 
many questions remain about the optimal strategies for the use of immunotherapies for the 
treatment of either newly diagnosed or recurrent ovarian cancer, but several studies are planned 
and are underway. Combinations of either chemotherapy and immunotherapy or two 
immunotherapy agents are under investigation. For example, nivolumab and ipilimumab (which 
has shown efficacy in melanoma) compared with nivolumab alone is being investigated, results 
from which are pending (235). More research is needed to understand the selection of optimal 
immunotherapy through the use of biomarkers, the effect of the tumor microenvironment on 
cancer growth and determining best and most effective therapeutic agents and combinations. 
 
Antibody–drug conjugates have shown single agent activity. One antibody drug conjugate, 
IMGN853, targets the folate- receptor and is linked to a highly potent maytansinoid that targets 
microtubules and suppresses microtubule dynamic instability, inducing cell-cycle arrest and cell 
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death (219). IMGN853 has demonstrated impressive single agent activity in patients with 
recurrent platinum-resistant ovarian cancer (219). 
 
One other strategy for therapeutic management of ovarian cancer is replacing mutated TP53 using 
gene therapy, as well as inhibition of MDM2 the ligase regulating p53 levels through small 
molecules). However, TP53 gene therapy using adenoviral vectors has been met with limited 
success partly due to toxicity related to the approaches used (157, 158). Other emerging therapies 
targeting tumors carrying mutant TP53 include COTI-2, which is thought to induce a ‘wild-type-
like’ conformational change in mutant p53 and is currently in clinical trials (159).  
 
[H3] Importance of tumour histology. With the improved understanding that ovarian cancer is 
composed of several histologically and molecularly distinct subtypes, certain classes of 
therapeutics have histology-specific mechanisms of action, such as PARP inhibitors for treatment 
of HGSC and MEK inhibitors for treatment of LGSC. Activity of the MEK inhibitor selumetanib 
in LGSC has been demonstrated (210); clinical trials comparing the use of MEK inhibitors to 
chemotherapy for the treatment of recurrent LGSC are underway; including a phase III study of 
binimetinib (also known as MEK162), compared with physician’s choice of chemotherapy agent 
(MILO study) (211). However, the MILO study was terminated because of futility, based on a 
planned interim analysis showing that the hazard ratio for progression free survival crossed a 
predefined futility boundary. One other study assessing MEK inhibition for the management of 
LGSC is investigating trametinib (GSK 1120212) in patients with recurrent or progressive LGSC 
(212), but this study has been suspended due to problems with the drug supply. 
 
 39 
[H3] Drug approvals. One challenge for the development of new therapies in ovarian cancer is 
the approval mechanisms of the FDA and EMA. Demonstrating an improvement of overall 
survival is a requirement for regulatory approval, but is difficult to demonstrate in ovarian cancer; 
explanations for this are not fully understood, but possibly include the use of active study agents 
after disease progression, which dilutes the effect of the active agent on overall survival but not 
on PFS (243, 244). Additionally, the lack of subclassification of histologic subtypes for clinical 
trial eligibility might have diluted the efficacy of some therapeutic agents, such as bevacizumab 
and also because no biomarker currently exists to select patients to receive this therapy. Several 
groups are calling for the achievement of significant improvement in PFS, coupled with PRO 
measures demonstrating the benefit of treatment, as a reason for drug approval; approval of 
bevacizumab and olaparib was due to improvement in PFS, quality of life, duration of response or 
response rate though approvals based on PRO’s are rare (ref). The time frame between 
subsequent therapies (that is, the second PFS) or time between paracentesis or thoracentesis 
procedures could also be important measurements of patient benefit from a specific therapy. 
PROs should be a vital component of any phase III study, particularly those testing agents for 
potential regulatory approval for the treatment of ovarian cancer.  
  
 
 
Figure 1.  Histological subtypes of ovarian cancer.  
a | High grade serous carcinoma (HGSC) is characterized by severe nuclear atypia, high nuclear 
to cytoplasmic ratio and abundant mitoses. Papillary architecture (arrow)  is also often present. b | 
Serous tubal intraepithelial carcinoma (STIC) lesions share the same morphological features as 
HGSC, with severe atypia, mitoses and lack of polarity. STIC lesions are thought to be precursors 
for HGSC. c | Low grade serous carcinoma (LGSC) demonstrates papillary architecture, but only 
mild nuclear atypia and a lower nuclear to cytoplasmic ratio. d | Clear cell carcinoma is 
characterized by large atypical tumor cells with frequent clearing of the cytoplasm and stromal 
hyalinization . e | Endometrioid adenocarcinoma is characterized by gland formation that 
recapitulates endometrial glands and is graded based on cellular architecture and nuclear atypia. f 
| Mucinous adenocarcinoma shows mucin-filled tumour cells, with frequent goblet cell forms 
present. 
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Figure 2. CT scans from a patient with stage IV ovarian cancer  
a | Right and left pleural effusions (arrows). b | Peritoneal carcinomatosis (arrows)  . c | 
Large volume ascites and a peritoneal hepatic implant  (arrows) 
Figure 3. DNA repair mechanisms and ovarian cancer. A | The double-stranded break and 
homologous repair process begins with recognition of the damage by serine-protein kinase ATM 
(ATM); a series of steps leads to the recruitment of the BRCA complex. B | DNA mismatch 
repair is mediated by the MSH proteins, as well as the endonuclease PMS2 and PCNA. These 
DNA repair processes are aberrant in ovarian cancer owing to mutations in the proteins involved. 
 
Figure 4. Tumour burden in ovarian cancer. 
A | Surgical removal of ovarian tumours in a 63 year old patient with bilateral advanced stage 
high grade serous ovarian (HGSC) cancer. B | : Bilateral HGSC with peritoneal carcinomatosis 
and involvement of intestinal surfaces   C:  removal of a serosal tumor implant located on the 
surface of the liver  
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Table 1. Characteristics of ovarian cancer by histology, genomic characteristics, and active 
therapies  
 
Histological subtype Clinical findings Genetic 
characteristics 
Treatment options 
High grade serous 
carcinoma and high-
grade endometrioid 
carcinoma 
Can present with 
peritoneal 
carcinomatosis, ascites, 
pelvic mass 
Typically advanced 
stage at presentation 
Deficiencies in 
homologous 
recombination (50% of 
tumours) Associated 
with BRCA and TP53 
mutations 
Platinum-based 
chemotherapy and 
PARP inhibitors 
Tumours are initially 
sensitive to platinum-
based chemotherapy 
but most patients with 
advanced-stage cancer 
will recur . 
Low-grade serous 
carcinoma  
Presents in younger 
patients (median 
reported age 43-55 
years (95)) 
Can be early or late 
stage at presentation 
Associated with KRAS 
and BRAF mutations 
Tumours havegenomic 
stability 
MEK inhibitors and 
hormonal therapies 
Low-grade 
endometrioid 
carcinoma 
Can be associated with 
endometriosis 
 
Associated with PTEN, 
ARID1A, PIK3CA 
mutations. Can have 
microsatellite instability 
Possible hormonal 
therapies (not yet 
established)  
Clear cell carcinoma Can present with 
parenchymal metastases 
(in liver and lung) 
Can also be associated 
with hypercoagulability 
and hypercalcaemia.  
Associated with 
ARID1A and PIK3CA 
mutations 
Immunotherapy agents.  
Can be resistant to 
platinum-based 
chemotherapy. 
Mucinous carcinoma Presents in younger 
patients and is typically 
early stage at 
presentation. 
Associated with KRAS 
mutations 
Tends to be 
chemotherapy-
insensitive but are still 
treated initially with 
cytotoxic 
chemotherapy.  
 
MEK, mitogen-activated protein kinase kinase; PARP, poly (ADP ribose) polymerase. 
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Table 2. Functions of commonly mutated inherited genes associated with increased 
risk of ovarian cancer18, 22-25  
 
Gene  Protein  Protein function 
BRCA1  Breast cancer type 1 
susceptibility protein 
Critically involved in the repair of double 
strand breaks by homologous recombination  
Serves as scaffold for other proteins involved 
in double strand DNA repair mostly through 
homologous recombination deficiency 
BRCA2 stabilizes RAD51-ssDNA complexes 
BRCA2 Breast cancer type 2 
susceptibility protein 
 
BARD1 BRCA1-associated RING 
domain protein 1 
Forms a heterodimer with BRCA1 
This complex is essential for mutual stability  
BRIP1 Fanconi anemia group J 
protein 
Binds to BRCA1 
BRCA1-BRIP1complex is required for S-phase 
checkpoint activation 
PALB2 Partner and localizer of 
BRCA2 
Bridging protein that connects BRCA1 and 
BRCA2 at sites of DNA damage 
Helps load RAD51 onto ssDNA 
RAD51C DNA repair protein RAD51 
homolog 3 
Strand exchange proteins that bind to ssDNA 
breaks to form nucleoprotein filaments and 
initiate DNA repair  
RAD51D DNA repair protein RAD51 
homolog 4 
MSH2 
 
DNA mismatch repair 
protein Msh2 
Mismatch repair proteins that recognize and 
repair basepairing errors occurring during 
DNA replication 
Mutations in mismatch repair genes are 
associated with Lynch syndrome 
MLH1 DNA mismatch repair 
protein Mlh1 
 
MSH6 DNA mismatch repair 
protein Msh6 
 
PMS2 Mismatch repair 
endonuclease PMS2 
ssDNA, single-stranded DNA. 
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Table 3. Staging of ovarian cancer  
FIGO 
stage  
Description Corresponding 
TNM stage 
Stage I: Tumor confined to ovaries or fallopian tube(s) T1 
IA Tumor limited to one ovary (with ovarian capsule intact) or 
fallopian tube; no tumor on ovarian or fallopian tube surface; 
no malignant cells in the ascites or peritoneal washings 
T1a 
IB Tumor limited to both ovaries (with ovarian capsules intact) or 
fallopian tubes; no tumor on ovarian or fallopian 
tube surface; no malignant cells in the ascites or peritoneal 
washings 
T1b 
IC Tumor limited to one or both ovaries or fallopian tubes, with 
any of the following C substages:  
T1c 
IC1: Surgical spill  
IC2: Capsule ruptured before surgery or tumor on ovarian or 
fallopian tube surface 
IC3: Malignant cells in the ascites or peritoneal washings  
Stage II: Tumor involves one or both ovaries, or the fallopian tubes with 
pelvic extension below the pelvic brim or primary peritoneal cancer (Tp) 
T2 
IIA Extension and/or implant of tumour on uterus and/or fallopian 
tubes and/or ovaries 
T2a 
IIB Extension of tumour to other pelvic intraperitoneal tissues T2b 
Stage III: Tumor involves one or both ovaries, or the fallopian tubes, or 
primary peritoneal cancer with cytologically or histologically confirmed 
spread to the peritoneum outside the pelvis and/or metastasis to the 
retroperitoneal lymph nodes 
T3 
IIIA IIIA1: Positive retroperitoneal lymph nodes only 
(pathologically proven): 
IIIA1(i) Metastasis up to 10 mm in greatest dimension. 
IIIA1(ii) Metastasis >10 mm in greatest dimension. 
IIIA2: Microscopic extrapelvic (above the pelvic brim) 
peritoneal involvement with or without 
positive retroperitoneal lymph nodes. 
T1, T2, T3aN1 
IIIB Macroscopic peritoneal metastasis beyond the pelvis up to 2 
cm in greatest dimension, with or without metastasis to the 
retroperitoneal lymph nodes 
T3b/T3b/N1 
IIIC Macroscopic peritoneal metastasis beyond the pelvis > 2 cm in 
greatest dimension, with or without metastasis to the 
retroperitoneal lymph nodes (includes extension of tumor to 
capsule of liver and spleen without parenchymal involvement 
of either organ) 
T3c/T3cN1 
Stage IV: Distant metastasis excluding peritoneal metastases  
IVA Pleural effusion with positive cytology. Any T, any N or 
M1  
IVB Parenchymal metastases and metastases to extra-abdominal 
organs (including inguinal lymph nodes and lymph nodes 
outside of the abdominal cavity) 
Any T, any N or 
M1 
Adapted from (127). FIGO, The International Federation of Gynecology and Obstetrics; 
TNM, TNM Classification of Malignant Tumours. 
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Table 4. Key clinical trials in newly diagnosed ovarian cancer  
Study  Arms 
 
Comments Ref 
 
 
Adjuvant therapy  
GOG 111 IV cisplatin and cyclophosphamide Increase in PFS and overall survival 
with cisplatin/paclitaxel treatment. 
8 
IV cisplatin and paclitaxel 
AGO OVAR 3 IV cisplatin and paclitaxel No significant difference between 
PFS or overall survival between 
treatment arms  
10 
IV carboplatin and paclitaxel 
GOG 158 IV cisplatin and paclitaxel Carboplatin and paclitaxel were not 
inferior to cisplatin and paclitaxel  
11 
IV carboplatin and paclitaxel 
GOG 182 IV carboplatin and paclitaxel  No significant difference between 
PFS or overall survival between 
treatment arms 
9 
 Other platinum based doublets 
SCOTROC IV carboplatin and paclitaxel Similar PFS between study arms 
Less neuropathy observed with 
carboplatin and docetaxel treatment 
than with carboplatin and paclitaxel 
12 
IV carboplatin and docetaxel 
GOG 172 IV cisplatin and paclitaxel  Increase in PFS and overall survival 
with IP treatment compared with IV 
treatment 
143 
IP cisplatin and paclitaxel and IV 
paclitaxel 
JGOG 3016 IV carboplatin and paclitaxel every 
21 days 
Significant improvement in PFS and 
overall survival with dose dense 
therapy in patients with sub-optimally 
cytoreduced cancer. No difference in 
patients with optimally cytoreduced 
cancer  
  
144, 145 
IV carboplatin every 21 days and 
paclitaxel weekly (dose dense 
regimen) 
GOG 252  IP cisplatin, IV and IP paclitaxel 
and bevacizumab 
 
 
 
 
No difference in PFS between study 
arms 
 
Higher rates of hypertension, nausea 
and vomiting in IP cisplatin group 
147 
IP carboplatin, IV weekly paclitaxel 
and bevacizumab  
 
IV carboplatin, IV weekly 
paclitaxel and bevacizumab  
 
MITO-7  Weekly carboplatin and weekly 
paclitaxel 
 
 
No difference in PFS or overall 
survival  
149 
Carboplatin and paclitaxel every 3 
weeks 
MITO-2  Carboplatin and paclitaxel 
 
 
No difference in PFS or overall 
survival  
150 
Carboplatin and pegylated 
liposomal doxorubicin 
Neoadjuvant therapy  
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EORTC Upfront surgery followed by 
chemotherapy 
NACT followed by surgical 
cytoreduction was not inferior to 
surgical cytoreduction followed by 
adjuvant chemotherapy 
160 
NACT, interval cytoreductive 
surgery, followed by completion of 
chemotherapy 
Kehoe et al Upfront surgery followed by 
chemotherapy 
NACT followed by surgical 
cytoreduction was not inferior to 
surgical cytoreduction followed by 
adjuvant chemotherapy 
161 
NACT, interval cytoreductive 
surgery, followed by completion 
 
Maintenance therapy  
GOG 218 Carboplatin, paclitaxel and 
bevacizumab with bevacizumab 
maintenance 
Increase in PFS with the addition of 
bevacizumab 
151 
Carboplatin, paclitaxel and 
bevacizumab with placebo 
maintenance  
Carboplatin, paclitaxel and placebo 
with placebo maintenance 
ICON7 Carboplatin, paclitaxel and 
bevacizumab with bevacizumab 
maintenance  
 
Increase in PFS with the addition of 
bevacizumab 
152 
Carboplatin and paclitaxel 
 
GOG262  IV carboplatin and paclitaxel every 
21 days with or without 
bevacizumab  
No difference in PFS in intent to treat 
patients between dose dense and 21-
day dosing 
 
Increase in PFS in patients receiving 
dose-dense treatment versus those 
receiving dosing every 21 days who 
were not given bevacizumab 
 
No difference in PFS in patients not 
receiving bevacizumab 
148 
IV carboplatin every 21 days and 
IV weekly paclitaxel with or 
without dose-dense bevacizumab  
NCT00866697 Platinum-based chemotherapy and 
taxane maintenance therapy  
 
Improved PFS with the addition of 
pazopanib 
 
No difference in overall survival 
between groups 
156 
Platinum-based chemotherapy and 
taxane maintenance therapy with 
pazopanib  
 
 
AGO-OVAR 
12 
 
Carboplatin and paclitaxel 
 
Improved PFS, but more 
gastrointestinal toxicities, with 
nintedanib.  
154 
Carboplatin and paclitaxel with 
nintedanib 
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NCT01493505 Carboplatin and paclitaxel Results pending  155 
Carboplatin and paclitaxel with 
trebananib 
 
 
 
IP intraperitoneal; IV intravenous; NACT, neoadjuvant chemotherapy; PFS progression-free 
survival  
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Table 5. Key trials for treatment of recurrent ovarian cancer.  
 
Study  Arms Comments Ref 
Platinum-sensitive disease  
ICON4/AGO-
OVAR-2.2 
 
Carboplatin  
 
Increase in PFS 
and overall 
survival with the 
addition of 
paclitaxel 
180 
Carboplatin and 
paclitaxel 
OCEANS Carboplatin, gemcitabine 
and bevacizumab with 
bevacizumab maintenance 
therapy 
 
 
Increase in PFS 
with the addition 
of bevacizumab 
 
184 
Carboplatin and 
gemcitabine 
ICON6 Platinum-based 
chemotherapy and 
cediranib with cediranib 
maintenance therapy 
 
 
Significant 
improvement in 
PFS 
 
Overall survival 
results are 
pending 
185 
Platinum-based 
chemotherapy  
NOVA  Platinum-based 
chemotherapy for 
platinum-sensitive 
recurrence followed by 
maintenance niraparib  
 Significant 
improvement in 
PFS (in women 
with germline 
BRCA mutations 
or homologous 
recombination 
deficiency ) group 
for niraparib 
versus placebo  
Ref: 
www.Tesarobio.com 
press release June 
28, 2016 and ESMO 
2016 Oct 
Platinum-based 
chemotherapy for 
platinum-sensitive 
recurrence, followed by 
maintenance with placebo 
drug 
 
NCT00113607 Pegylated liposomal 
doxorubicin and 
trabectedin 
 
Pegylated liposomal 
doxorubicin 
Significant 
increase in PFS 
with the addition 
of trabectedin 
186 
NCT00753545 Platinum-based 
chemotherapy with or 
without olaparib 
maintenance therapy 
Significant 
increase in PFS 
with olaparib 
maintenance 
therapy 
200 
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NCT01081951 Carboplatin and paclitaxel 
with or without olaparib 
maintenance therapy 
Increase in PFS 
with olaparib 
maintenance 
therapy 
201 
Platinum-resistant disease  
AURELIA Paclitaxel with or without 
bevacizumab 
 
 
 
 
Increased PFS and 
response rate with 
the addition of 
bevacizumab. 
 
Paclitaxel + 
bevacizumab was 
the best 
combination – 
increased response 
rate, PFS and 
overall survival. 
 
 
 
187, 188 
Pegylated liposomal 
doxorubicin with or 
withoutbevacizumab 
 
Topotecan with or 
withoutbevacizumab 
 
PFS, progression-free survival. 
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Table 6. Ongoing clinical trials for treatment of ovarian cancer 
Type of biologic 
therapy 
Example Target Comments Ref  
Anti-angiogenics Bevacizumab 
Cediranib  
VEGF 
 
VEGFR1, 2, 3 
Single agent 
activity in both 
platinum-resistant 
and platinum-
sensitive cancer  
 
184, 185, 
187-194 
PARP inhibitors Olaparib 
 
 
 
 
PARP Olaparib approved 
by the EMA for 
treatment of 
platinum-sensitive 
recurrent cancer as a 
maintenance therapy 
and by the FDA for 
recurrent ovarian 
cancer in women 
with germline BRCA 
mutations and who 
have received at 
least 3 prior lines of 
chemotherapy 
 
 
193-202, 
204-208, 245 
Rucaparib Results pending 
Veliparib Results pending 
Immunotherapies Nivolumab  
 
 
 
 
Programmed 
cell death 
protein-1  
 
 
 
 
 
 
 
15% response rate 
and 50% disease 
control rate 
 
 
214 
 
 
 
 
 
 
 
 
 
 
Pembrolizumab  
 
Programmed 
cell death 
protein-1 
 
11.5% response rate 
and 23.1% of 
patients had stable 
disease 
 
 
215 
 
 50 
Avelumab  Programmed 
cell death 1 
ligand 1 
 
10.7% risk reduction 
and 54.7% disease 
control rate. 2 
patients with a clear 
cell histology 
showed evidence of 
an objective 
response rate. 
 
 
216 
 
Ipilimumab  Cytotoxic T-
lymphocyte 
protein 4 
Results pending 217, 218 
Antibody–drug 
conjugate  
IMGN853  Folate receptor 
 
Promising 
preliminary data  
219 
Combination  Cediranib and 
olaparib  
 
 
 
 
Various Increased PFS in 
patients that 
received 
cediranib/olaparib, 
compared with 
patients receiving 
olaparib alone. 
Currently being 
tested in phase III 
studies in both 
platinum-resistant as 
well as platinum-
sensitive recurrent 
cancer  
193, 194, 238 
 
 
 
 
 
 
Pembrolizumab 
and niraparib 
Results pending  240 
BKM120 or 
BYL719 and 
olaparib 
Maximum tolerated 
dose achieved for 
BKM120 and 
olaparib; anti-cancer 
activity noted for 
this combination 
239 
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